Based on findings from a rabbit thrombogenicity test and rat or monkey repeated-dose toxicity studies, eftrenonacog alfa displays no special hazards for humans. Studies to investigate the genotoxicity, carcinogenicity, toxicity to reproduction or embryo-foetal development have not been conducted. Eftrenonacog alfa has shown to cross the placenta in small amounts according to a mouse placental transfer study FDA Label.
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H) A31556. The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis.
Hemophilia B is a blood disorder with an incidence of approximately once every 30,000 male births in all populations and ethnic groups A31557. It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding episodes caused spontaneously or as a result of accidental or surgical trauma FDA Label. When untreated, most patients die from bleeding complications before 25 years of age A31557. Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.
Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. Eftrenonacog alfa treatment demonstrated good tolerability with no reports of inhibitor development in clinical studies A31556.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Eftrenonacog alfa. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estrone | Estrone may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estradiol | Estradiol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Mestranol | Mestranol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estriol | Estriol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Tibolone | Tibolone may increase the thrombogenic activities of Eftrenonacog alfa. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eftrenonacog alfa. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eftrenonacog alfa. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Eftrenonacog alfa. |
| Zeranol | Zeranol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Equol | Equol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Promestriene | Promestriene may increase the thrombogenic activities of Eftrenonacog alfa. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Eftrenonacog alfa. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Eftrenonacog alfa. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Eftrenonacog alfa. |
| Formononetin | Formononetin may increase the thrombogenic activities of Eftrenonacog alfa. |
| Estetrol | Estetrol may increase the thrombogenic activities of Eftrenonacog alfa. |
| Aminocaproic acid | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Eftrenonacog alfa. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Eftrenonacog alfa. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eftrenonacog alfa. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Eftrenonacog alfa. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Eftrenonacog alfa. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eftrenonacog alfa. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Eftrenonacog alfa. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eftrenonacog alfa. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Eftrenonacog alfa. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Eftrenonacog alfa. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Eftrenonacog alfa. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eftrenonacog alfa. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Eftrenonacog alfa. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eftrenonacog alfa. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eftrenonacog alfa. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Eftrenonacog alfa. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eftrenonacog alfa. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Eftrenonacog alfa. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Eftrenonacog alfa. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Eftrenonacog alfa. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eftrenonacog alfa. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eftrenonacog alfa. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Eftrenonacog alfa. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Eftrenonacog alfa. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eftrenonacog alfa. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Eftrenonacog alfa. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Eftrenonacog alfa. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Eftrenonacog alfa. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Eftrenonacog alfa. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Eftrenonacog alfa. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Eftrenonacog alfa. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Eftrenonacog alfa. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Eftrenonacog alfa. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Eftrenonacog alfa. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Eftrenonacog alfa. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Eftrenonacog alfa. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Eftrenonacog alfa. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Eftrenonacog alfa. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Eftrenonacog alfa. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Eftrenonacog alfa. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eftrenonacog alfa. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Eftrenonacog alfa. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Eftrenonacog alfa. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Eftrenonacog alfa. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Eftrenonacog alfa. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Eftrenonacog alfa. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Eftrenonacog alfa. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Eftrenonacog alfa. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eftrenonacog alfa. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Eftrenonacog alfa. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Eftrenonacog alfa. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eftrenonacog alfa. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eftrenonacog alfa. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Eftrenonacog alfa. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Eftrenonacog alfa. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eftrenonacog alfa. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Eftrenonacog alfa. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Eftrenonacog alfa. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Eftrenonacog alfa. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Eftrenonacog alfa. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Eftrenonacog alfa. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Eftrenonacog alfa. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Eftrenonacog alfa. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Eftrenonacog alfa. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eftrenonacog alfa. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Eftrenonacog alfa. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Eftrenonacog alfa. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Eftrenonacog alfa. |